Cinvanti Generic: When Will Generic Aprepitant Be Available?
This page is aggregated from FDA records, court filings and company announcements. Coded and designed by Dr. Brian Staiger, PharmD, BCPS
Updated October 9, 2026 How we build our data
Cinvanti Generic at a Glance
Four quick answers from FDA records and our estimate.
- When is the first generic expected? June 2032 About 5.5 years away Why then?
- Has the FDA approved a generic? March 2026 Since discontinued Why not yet?
- When does the last patent end? September 2035 13 patents listed with the FDA Why is a generic expected sooner?
- Can you buy a generic today? Not yet No company lists one for sale
Generic aprepitant is expected to be available in June 2032, about 5.5 years away. None is for sale yet.
Why June 2032?
The patent fight is likely to end in an agreement that sets the launch. The terms are not public yet. We rate it probable: more likely than not, but it can still move.
If Cinvanti’s last patent runs to September 2035, how can a generic come sooner?
The 13 patents that run past the expected month, to September 2035 (9,561,229, 9,808,465, 9,974,742, 9,974,793 and 9 more), cover the product’s formulation and a way of using it. A patent like that protects one way of making or using the medicine, not the medicine itself. A generic company can often make its version a different way or leave that use off its label, or a court can rule the patent invalid or not infringed. Here, the companies are expected to settle on a date. Generic companies have been challenging Cinvanti’s patents with the FDA since April 2022. That is why the expected month comes before the last protection ends. See the road to a generic
Why hasn’t the FDA approved a generic yet?
That is normal before a launch. The FDA usually can’t give a generic its final approval while a patent or exclusivity still blocks it, so final approval often comes close to the day the generic can be sold. No company holds a “tentative” approval yet either (the FDA’s word for a generic that is ready but still blocked).
Will the generic cost less?
Usually, and more so as more companies sell one. 4 companies have applied to the FDA to make it. In the FDA’s study of past launches, pharmacies paid about 73% less once four companies sold a generic. See the price pattern
What should I do now?
Keep taking Cinvanti as prescribed. When a generic arrives, your pharmacy may switch you to it automatically, and it may look different. What a generic means for you
Our month is only an estimate based on available information, so we never name a day.
Cinvanti by the Numbers
- Reason
- Settlement expectedThe patent fight is likely to end in an agreement that sets the launch. The terms are not public yet.
- How sure
- Probable More likely than not, but it can still move.
- Price competition
- Strong 4 companies have filed, 1 first in line
- Brand sales
- $327M a yearBig seller
- FDA approved 2017 November 2017 FDA Orange Book
- Patents listed 13 last runs to September 2035 A generic is expected sooner, in June 2032. See why FDA Orange Book
- Medicare Part D spent $629.6K in 2025, for 269 people CMS Part D Spending by Drug
- Medicaid prescriptions 27.2K in the last four reported quarters, $9.8M CMS Medicaid drug utilization, to Q1 2026
Cinvanti’s Road to a Generic
Cinvanti has had the market to itself since the FDA approved it in November 2017 (Heron Therapeutics Inc). Its 13 listed patents run to September 2035. Generic companies have challenged its patents with the FDA since April 2022.
The first generic of Cinvanti is expected in June 2032.
Why that month: the patent fight is likely to end in an agreement that sets the launch. The terms are not public yet. That is about 3.5 years before the last listed patent runs out, in September 2035.
Why a Generic Can Come Before September 2035
The last listed patent runs to September 2035, but it covers the product’s formulation and a way of using it, not the medicine itself, which a generic can often work around or challenge. Dr. Brian explains
Each bar runs from the brand’s approval to the day that protection ends. The green band is our projection for the first generic: a month, never a day, because legal dates move and a generic reaches shelves days to weeks after it is allowed. Sources: FDA Orange Book; the expected month from court records and company announcements.
Cinvanti Patents and FDA Protections
Every patent and exclusivity the FDA Orange Book lists for Cinvanti’s own applications. A protection running past the expected month does not mean the date is wrong: a settlement or a court ruling can let a generic in before a patent ends, and a patent on one formulation or use does not block every generic.
| Patent | What it covers | Protects until | Status |
|---|---|---|---|
| 9,561,229 | The product’s formulation; a way of using it (U-2161) | September 2035 | Active |
| 9,808,465 | A way of using it (U-2161) | September 2035 | Active |
| 9,974,742 | The product’s formulation | September 2035 | Active |
| 9,974,793 | The product’s formulation | September 2035 | Active |
| 9,974,794 | The product’s formulation; a way of using it (U-2161) | September 2035 | Active |
| 10,500,208 | The product’s formulation | September 2035 | Active |
| 10,624,850 | A way of using it (U-2161) | September 2035 | Active |
| 10,953,018 | A way of using it (U-2161) | September 2035 | Active |
| 11,173,118 | The product’s formulation | September 2035 | Active |
| 11,744,800 | The product’s formulation | September 2035 | Active |
| 12,115,254 | The product’s formulation | September 2035 | Active |
| 12,115,255 | The product’s formulation | September 2035 | Active |
| 12,290,520 | The product’s formulation | September 2035 | Active |
Source: FDA Orange Book, application 209296. Patent numbers open the patent on Google Patents.
Patent Challenges to Cinvanti
The first patent challenge to Cinvanti reached the FDA in April 2022, from one company on that first day. The FDA has not approved a first challenger’s generic yet.
What Is a Patent Challenge?
A generic company that wants to sell its version before Cinvanti’s patents run out can tell the FDA that a patent is invalid, or that its version does not infringe it. The FDA calls this a “Paragraph IV certification.” The brand company usually sues, and the FDA then generally cannot approve that generic for up to 30 months while the case runs. To reward going first, the companies that challenge first can get a 180-day head start: the FDA cannot approve the generics that came after them until it ends.
| Product | First challenged | Companies that day | 180-day head start | First challenger’s generic | Challenged patents run to | |
|---|---|---|---|---|---|---|
| Approved | On sale | |||||
| Intravenous emulsion, 130 mg/18 mL | April 2022 | 1 company | Head start still held decided December 2025 | Not yet | Not yet | September 2035 |
Source: the FDA’s Paragraph IV Patent Certifications list, as of September 2026. The FDA began posting the 180-day decisions and the first challenger’s approval and first sale in June 2019: an older entry it has not updated since reads “Not posted”, and “Not yet” means the list records no such event. “Companies that day” is the FDA’s count of challenges that arrived on the first day.
Who Is Lined Up to Make Generic Aprepitant
Three steps stand between a brand and a generic you can buy: a company applies to the FDA, the FDA approves it, and the company starts selling it.
Applied to the FDA
4 companies have applied to the FDA to make generic aprepitant.
The FDA names a company only once it approves its application, even tentatively, and it has not done that for these yet, so the companies are not named here. Names often come out in the brand company’s patent lawsuits or in the companies’ own announcements.
First in line. One of them was first in line: the first company to challenge the brand’s patents can earn 180 days on the market before the other generics, which is why being first matters.
Generic companies have challenged Cinvanti’s patents with the FDA since April 2022: see the patent challenges.
Approved by the FDA
Not yet. The FDA has not approved a generic aprepitant. Final approval often comes close to the day a generic can be sold.
For Sale in Pharmacies
Not yet. No company lists a generic aprepitant for sale with the FDA.
| Company | First approved | Strengths | Rated |
|---|---|---|---|
| Mylan Pharmaceuticals Inc discontinued | March 2026 | 32MG/4.4ML (7.2MG/ML) | – |
Sources: how many companies have applied, from court records and company announcements; approved generics from the FDA Orange Book; tentative approvals from Drugs@FDA; what is for sale from the FDA NDC Directory. The FDA does not disclose an application before it approves it (21 CFR 314.430).
Cinvanti Price: What Pharmacies Pay and What Generics Usually Do
What a Generic Could Cost
How we estimate it. The national survey of what pharmacies pay (NADAC) has no recent price for Cinvanti, so we cannot show dollars. Here is the FDA’s finding of how far the price pharmacies pay usually falls as generic companies join: about 31% with one company, 44% with two, 73% with four and over 95% with six or more (the typical drop for every drug whose first generic came out from 2015 to 2017).
Median prices pharmacies paid for the generic (invoice prices), compared with the brand’s price before generic entry, from FDA’s 2019 analysis “Generic Competition and Drug Prices”. At the manufacturer’s price FDA found steeper drops (about 39%, 54%, 79% and over 95%), the figures quoted elsewhere on this tracker. A typical pattern, not a price quote for this medicine.
What Medicare and Medicaid Spend on Cinvanti
Big public spending is part of why generic makers line up for a medicine, and why its first generic matters beyond the pharmacy counter. Figures are before manufacturer rebates, which are confidential.
Medicare Part D Spending
What Medicare drug plans spent on Cinvanti, before manufacturer rebates.
- $123.6K
- January to March 2026, the latest CMS has posted
For 98 people, about $672 per prescription fill - $629.6K
- 2025, the whole year
For 269 people, about $611 per prescription fill
See the numbers
| Period | Spending | People | Per fill |
|---|---|---|---|
| January to March 2026 | $123,602 | 98 | $671.75 |
| 2025 | $629,552 | 269 | $610.62 |
Source: CMS Medicare Part D Spending by Drug, matched by the brand name Cinvanti only, so no generic is counted in it. What CMS says it is used for: Aprepitant is used to prevent nausea and vomiting caused by cancer drug treatment (chemotherapy) or surgery. It works by blocking one of the body's natural substances (substance P/neurokinin 1) that causes vomiting.
Medicaid Prescriptions by Quarter
27,201 prescriptions in the four quarters to Q1 2026, $9.8M paid.
See the numbers
| Quarter | Prescriptions | Medicaid paid |
|---|---|---|
| Q1 2026 | 4,832 | $1,544,029 |
| Q4 2025 | 6,588 | $2,446,372 |
| Q3 2025 | 7,684 | $2,911,545 |
| Q2 2025 | 8,097 | $2,896,720 |
| Q1 2025 | 8,560 | $3,465,267 |
Source: CMS Medicaid State Drug Utilization Data, over Cinvanti’s own package codes.
Cinvanti Strengths and Forms
| Strength | Form | How it is taken | Approved | Status |
|---|---|---|---|---|
| 130MG/18ML (7.2MG/ML) | Emulsion | Intravenous | November 2017 | Prescription reference product |
Source: FDA Orange Book, Heron Therapeutics Inc. Listed for sale today by Heron Therapeutics, Inc. (FDA NDC Directory).
Cinvanti NDC Codes and Packages
Each Cinvanti package sold today has its own NDC, the product number printed on the box and on the pharmacy label. Open one to see that package’s details, what pharmacies pay for it and its patent timeline.
| NDC | Product | Package | Company |
|---|---|---|---|
| 47426-0201-01 | APREPITANT 130 mg/18mL injection, emulsion | vial of 18 mL | Heron Therapeutics, Inc. |
| 47426-0201-01 | APREPITANT 130 mg/18mL injection, emulsion | vial of 18 mL | Heron Therapeutics, Inc. |
Source: the FDA NDC Directory, current listings only. Only packages sold under Cinvanti’s own FDA approval (NDA 209296) are listed, never a generic. Some codes belong to companies that repackage Cinvanti: it is the same medicine in a different package.
What a Generic Cinvanti Means for You
Nothing Changes Until It Is in Pharmacies
Until a generic is actually for sale, keep filling Cinvanti as usual. When one arrives, there is nothing you need to sign up for.
Your Pharmacy May Switch You Automatically
Every state lets pharmacists fill a brand-name prescription with an FDA-approved generic rated as equivalent to it, and about 19 states require them to, unless your prescriber writes “dispense as written” or “brand medically necessary” on the prescription. Some states ask the pharmacist to tell you, or to get your OK first. A study of every state’s law has the details.
It Will Probably Look Different
US trademark law does not let a generic look exactly like the brand, so the color, shape or markings usually change. The active ingredient, strength and form are the same. An “authorized generic,” made by or for the brand’s own company, can look identical. The FDA explains.
Your Insurance May Change Too
Once a lower-cost version is available, many insurance plans charge more for the brand, or stop covering it. Your plan’s drug list (formulary) says how.
Until a generic is on US pharmacy shelves, be careful with websites that offer “generic Cinvanti”. The FDA warns that unlicensed online pharmacies sell counterfeit and unapproved medicines; its BeSafeRx page shows how to check a pharmacy.
Questions people ask about Cinvanti
Is there a generic for Cinvanti right now?
No. As of October 9, 2026 no generic aprepitant is listed for sale in the FDA NDC Directory. 1 generic version is FDA-approved (Orange Book), which usually means it is waiting on patents or on the maker’s own launch plans.
When will Cinvanti go generic?
June 2032 is the expected month, and that is probable but not certain. The patent fight is likely to end in an agreement that sets the launch. The terms are not public yet. The last listed patent runs to September 2035, but it covers the product’s formulation and a way of using it, not the medicine itself, which a generic can often work around or challenge.
Will generic aprepitant be the same as Cinvanti?
Yes in the ways that matter: the same active ingredient, strength and form, with proof that it reaches your blood the same way. Inactive ingredients can differ, which is why some people notice a different look or taste.
How much will the generic cost?
Nobody can say for sure before launch. 4 companies have applied to the FDA to make it. In the FDA’s study of past launches, pharmacies paid about 73% less once four companies sold a generic. That is a pattern from past launches, not a prediction for this one.
Has the FDA approved a generic Cinvanti?
Not yet. The FDA Orange Book lists no approved generic version of Cinvanti that is still marketed.
When does the Cinvanti patent expire?
The FDA Orange Book lists 13 patents for Cinvanti; the last runs to September 2035. A patent date is not the launch date: settlements and court rulings often bring a generic earlier, and FDA approval or a company’s own plans can make it later. The expected month on this page (June 2032) weighs all of that.
Has anyone challenged the Cinvanti patents?
Yes. The first patent challenge to Cinvanti reached the FDA in April 2022, from one company on that first day. The FDA has not approved a first challenger’s generic yet. A patent challenge (a “Paragraph IV certification”) is a generic company telling the FDA that a patent listed for the brand is invalid or will not be infringed by its version. The first companies to file one can earn a 180-day head start, during which the FDA cannot approve the generics that filed after them.
Changes to This Projection
- First generic expected June 2032 on this month’s schedule. A line is added here whenever a monthly update moves the month, the reason or how sure it is.
Every change to the expected month is logged here with the month we saw it.
Also Going Generic
- VyzultaLatanoprostene Bunod2028 to 2029
- SteglujanErtugliflozin and Sitagliptin PhosphateDecember 2031
- OpzeluraRuxolitinib Phosphate2034 to 2035
- EmpaveliPegcetacoplanDecember 2038
- JuvisyncSimvastatin and Sitagliptin PhosphateTBD no date yet
- AtorvaliqAtorvastatin CalciumTBD no date yet
About Cinvanti
- Generic name aprepitant
- How it is taken Into a vein (IV)
- Company Heron Therapeutics Inc
- Hard to copy Inhalers, injectables, patches and other hard-to-copy products. Fewer companies attempt them and dates slip more often.
- Patent challenges Since April 2022 (FDA)
- More drugs Brand-name drugs starting with C
- Have a question? A pharmacist answers, free. Ask about Cinvanti
Sources. The expected month: FDA Paragraph IV Patent Certifications list, federal court records, company announcements and securities filings (settlement dates, launch plans, sales). The record on this page: FDA Orange Book, Drugs@FDA (tentative approvals), FDA NDC Directory, FDA Paragraph IV Patent Certifications list, CMS Medicare Part D Spending by Drug, Medicaid State Drug Utilization Data, FDA, Generic Competition and Drug Prices (2019). Updated October 9, 2026. Information, not medical advice.